CRL Stock Forecast & Price Target

Charles River is supported by a durable outsourced preclinical platform, with 5%-7% organic revenue growth and LDD% adjusted EPS growth targets through 2030 that appear conservative relative to improving demand and pricing in DSA. The company’s DSA segment offers the most upside through BioA expansion, with management expecting roughly one-quarter of DSA revenue growth over the LRP to come from BioAnalysis, while Create the Future and Apollo provide credible margin leverage. Manufacturing adds further quality to the mix, with 7%-9% organic growth and >40% adjusted operating margins by 2030, and the business also benefits from a strong NAMs portfolio, recurring consumables, and an implied $0.20-$0.25 2027 refinancing headwind that still leaves earnings growth intact.

Charles River is facing a negative fundamental setup because demand for preclinical and IND-enabling work could weaken if biotech capital constraints persist, pharma pipelines stay focused on later-stage assets, or customers shift more development in-house. The company also carries execution risk from its strategic review and vertical integration efforts, since management’s expected 2026 and 2027 EPS accretion from lower NHP procurement costs and about 120 basis points of margin uplift may not materialize if integration, supply chain, or utilization issues emerge. In addition, structural pressure from NAMs adoption could erode its highest-margin DSA business, especially if organ-on-chip, organoid, and in silico methods gain FDA acceptance faster than expected and offset CRL’s ~$120M of limited NAMs exposure.